The Week

Medtronic (MDT) fell 2.27% this week to close at $91.23, while the S&P 500 gained 0.49%, a relative underperformance of roughly 2.76 percentage points. The stock opened the week with a push to $94.05 on Monday, then slid through Tuesday, hit a low of $89.94 on Thursday, and bounced back above $91 on Friday. The week played out as a pullback after an early rise, with a range of 4.4%.

Key Events

The most company-specific development was an FDA early alert on 27 August for Medtronic’s esophageal pH monitoring capsule delivery device, raising a product-safety regulatory concern. Earlier in the week, Medtronic announced a partnership with OnTrac AI to help credit unions build AI readiness, extending its push into healthcare services and digital tools. Attention also turned to the fiscal Q1 2027 earnings report due on 1 September, with several analysts revising forecasts ahead of the call. Across the sector, Boston Scientific saw operational disruption from a cybersecurity incident, and medical device names traded unevenly; Medtronic underperformed peers on multiple days. The week’s only material filing was an ARS annual report, with no major operating announcements.

Analyst Ratings

Thirty firms cover the stock: 17 rate it buy, 3 overweight, 9 hold, and 1 has no opinion, with no underweight or sell ratings. The consensus rating is buy, and the consensus target of $98.84 sits about 8.3% above the current price of $91.23. Targets range from $78 to $121, a wide spread that shows disagreement on valuation. Within the medical device industry, Medtronic ranks 3rd out of 141 companies.

The Week Ahead

Medtronic reports fiscal Q1 2027 results before the open on Tuesday, 1 September, with consensus estimates of $1.0002 EPS and $9.545 billion in revenue. The same week brings US ISM manufacturing PMI, JOLTS job openings, and ADP private payrolls; macro data could shift risk appetite for healthcare names. Earnings will be the main test of whether the recent pullback has reset the valuation to a more defensible level.

In Short

The stock’s decline this week coincided with the FDA alert, sector divergence, and cautious positioning before earnings, while analyst ratings remain largely favourable and the consensus target sits above spot. On valuation, the stock trades at about 24.3x earnings and 2.36x book, with a dividend yield near 3.12%. Latest-session flows show large-lot money as a net seller while medium and small lots were net buyers, pointing to an uneven tone. The tension now is whether the earnings report can support current multiples and whether the regulatory issue expands.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.